Method of treating or inhibiting the development of brain inflammation and sepsis

Abstract

A leukotriene C4 and D4 antagonist is used to treat or inhibit brain inflammation and sepsis by acting to inhibit increased capillary permeability and white blood cell extravasation. Potential candidate compounds can be screened in a non-human mammal before or after administration of an inflammation inducing agent into the subarachnoid space by determining their ability to inhibit increased capillary permeability and white blood cell extravasation.

1 . A method for treating or inhibiting the development of brain inflammation due to a stroke, comprising administering to a mammal in need thereof a therapeutically effective amount of pranlukast or a pharmaceutically acceptable salt thereof, which does not cross or minimally crosses the blood brain barrier, to treat or inhibit the development of brain inflammation due to a stroke.  
   
   
       2 . The method of  claim 1 , further comprising repeating the administering step until the white blood cell count reaches a normal level in cerebrospinal fluid.  
   
   
       3 . The method of  claim 1 , wherein the therapeutically effective amount of pranlukast is in a range of about 100 mg/day to 2000 mg/day.  
   
   
       4 . The method of  claim 1 , wherein the therapeutically effective amount of pranlukast is in a range of about 200 mg/day to 1000 mg/day.  
   
   
       5 . The method of  claim 1 , wherein the therapeutically effective amount of pranlukast is in a range of about 400 mg/day to 800 mg/day.  
   
   
       6 . The method of  claim 1 , wherein the mammal is a human.